DelSiTech Ltd. today announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology. Dexamethasone ...
Optifye Therapeutics has struck a deal with DelSiTech for controlled-release dexamethasone eye drops. The exclusive license agreement covers a candidate that uses DelSiTech Silica Matrix technology to ...
Please provide your email address to receive an email when new articles are posted on . Putting an eye drop in a young kid’s eye is tough. Putting an eye drop in your own young kid’s eye is impossible ...
Please provide your email address to receive an email when new articles are posted on . This two-part series reviews innovative sustained-delivery options for both long- and short-term indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results